Literature DB >> 25108897

The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Katarina Eeg-Olofsson1, Soffia Gudbjörnsdottir2, Björn Eliasson2, Björn Zethelius3, Jan Cederholm4.   

Abstract

AIMS: Assessing the association between BMI and risk of coronary heart disease (CHD), cardiovascular disease (CVD) and mortality in patients with type 2 diabetes, also with regard to higher or lower levels of the ratio triglycerides-to-HDL-cholesterol (TG:HDL).
METHODS: 54,061 patients with BMI≥18.5kg/m(2), mean age and duration 61.5±8 and 6.9±6 years, 59% males, 14% with CVD history, from the Swedish National Diabetes Register, followed for mean 4.8 years.
RESULTS: Adjusting at Cox regression for non-BMI-linked (age, sex, smoking, CVD history) and BMI-linked (blood lipids, blood pressure, HbA1c, albuminuria) covariates, hazard ratios (HR) for fatal/nonfatal CHD and CVD were mainly increased with prominent obesity (BMI≥35kg/m(2)), 1.19 (p=0.01) and 1.17 (p=0.009), compared to normal weight (BMI 18.5-24.9kg/m(2)), although increased also with obesity (BMI 30-34.9kg/m(2)), 1.34 and 1.30 (p<0.001), when adjusting only for non-BMI-linked covariates. Stratifying by 75th percentile of TG:HDL, with normal weight and TG:HDL<1.9 as reference, obese and prominently obese with TG:HDL≥1.9 had considerably increased HR around 1.7 for fatal/nonfatal CHD and 1.6 for CVD (p<0.001), while obese and prominently obese with TG:HDL<1.9 only had HR 1.2-1.3 for CHD and CVD (p0.003-<0.01).
CONCLUSION: Obese T2D patients with high TG:HDL, associated with increased insulin resistance, had considerably increased risk of CHD and CVD.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  BMI; Cardiovascular diseases; Diabetes; Insulin resistance; Obesity

Mesh:

Substances:

Year:  2014        PMID: 25108897     DOI: 10.1016/j.diabres.2014.07.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  17 in total

1.  Characterization of gut microbiota composition in HIV-infected patients with metabolic syndrome.

Authors:  María Jesús Villanueva-Millán; Patricia Pérez-Matute; Emma Recio-Fernández; José-Miguel Lezana Rosales; José-Antonio Oteo
Journal:  J Physiol Biochem       Date:  2019-03-28       Impact factor: 4.158

2.  Triglyceride to high density lipoprotein cholesterol ratio and its association with periodontal disease in Korean adults: findings based on the 2012-2014 Korean national health and nutrition examination survey.

Authors:  Yu-Jin Kwon; Jeong-Won Park; Hyoung-Ji Lim; Yong-Jae Lee; Hye-Sun Lee; Jae-Yong Shim
Journal:  Clin Oral Investig       Date:  2017-06-06       Impact factor: 3.573

3.  Isolated Hyperthyrotropinemia Adversely Influences Lipid Metabolism in Children and Adolescents with Obesity.

Authors:  Deniz Özalp Kızılay; Şebnem Uysal Ateş
Journal:  Turk Arch Pediatr       Date:  2022-05

4.  Prediction of incident hypertension and arterial stiffness using the non-insulin-based metabolic score for insulin resistance (METS-IR) index.

Authors:  Omar Yaxmehen Bello-Chavolla; Neftali E Antonio-Villa; Arsenio Vargas-Vázquez; Alexandro J Martagón; Roopa Mehta; Olimpia Arellano-Campos; Donaji V Gómez-Velasco; Paloma Almeda-Valdés; Ivette Cruz-Bautista; Marco A Melgarejo-Hernandez; Liliana Muñoz-Hernandez; Luz E Guillén; José de Jesús Garduño-García; Ulices Alvirde; Yukiko Ono-Yoshikawa; Ricardo Choza-Romero; Leobardo Sauque-Reyna; Ma Eugenia Garay-Sevilla; Juan M Malacara-Hernandez; María T Tusié-Luna; Luis M Gutierrez-Robledo; Francisco J Gómez-Pérez; Rosalba Rojas; Carlos A Aguilar-Salinas
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-18       Impact factor: 3.738

5.  The Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio to Predict New Cardiovascular Events in Essential Hypertensive Patients.

Authors:  Osman Turak; Barış Afşar; Fırat Ozcan; Fatih Öksüz; Mehmet Ali Mendi; Çagrı Yayla; Adrian Covic; Nathan Bertelsen; Mehmet Kanbay
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738

6.  Association of a Human FABP1 Gene Promoter Region Polymorphism with Altered Serum Triglyceride Levels.

Authors:  Xian-E Peng; Yun-Li Wu; Yi-Bing Zhu; Rong-Dong Huang; Qing-Qing Lu; Xu Lin
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

7.  Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.

Authors:  Charlotte Vaysse; Jon Lømo; Øystein Garred; Frøydis Fjeldheim; Trygve Lofteroed; Ellen Schlichting; Anne McTiernan; Hanne Frydenberg; Anders Husøy; Steinar Lundgren; Morten W Fagerland; Elin Richardsen; Erik A Wist; Catherine Muller; Inger Thune
Journal:  NPJ Breast Cancer       Date:  2017-05-03

8.  Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry.

Authors:  Viral N Shah; Ryan Bailey; Mengdi Wu; Nicole C Foster; Rodica Pop-Busui; Michelle Katz; Jill Crandall; Fida Bacha; Kristen Nadeau; Ingrid Libman; Paul Hiers; Kara Mizokami-Stout; Linda A DiMeglio; Jennifer Sherr; Richard Pratley; Shivani Agarwal; Janet Snell-Bergeon; Eda Cengiz; Sarit Polsky; Sanjeev N Mehta
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

9.  The Correlation between the Triglyceride to High Density Lipoprotein Cholesterol Ratio and Computed Tomography-Measured Visceral Fat and Cardiovascular Disease Risk Factors in Local Adult Male Subjects.

Authors:  Hye-Rin Park; Sae-Ron Shin; A Lum Han; Yong Joon Jeong
Journal:  Korean J Fam Med       Date:  2015-11-20

10.  Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

Authors:  Paul Valensi; Antoine Avignon; Ariane Sultan; Bernard Chanu; Minh Tuan Nguyen; Emmanuel Cosson
Journal:  Cardiovasc Diabetol       Date:  2016-07-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.